John Kane, MD

Articles by John Kane, MD

LB-102 Significantly Improves Disease Severity in Acute Schizophrenia, with John Kane, MD

April 12th 2025

HCPLive spoke with Kane about new phase 2 data showing that an oral benzamide provides a significant change from baseline in CGI-S scores for participants with acute schizophrenia.

John Kane, MD | Credit: Northwell Health

Phase 2 LB-102 Data, Advancing Treatment Landscape in Schizophrenia, with John Kane, MD

ByChelsie Derman,John Kane, MD

January 10th 2025

HCPLive spoke with John M. Kane, MD, about phase 2 LB-102 data for schizophrenia.

John Kane, MD

Articles by John Kane, MD

LB-102 Significantly Improves Disease Severity in Acute Schizophrenia, with John Kane, MD

Phase 2 LB-102 Data, Advancing Treatment Landscape in Schizophrenia, with John Kane, MD

Latest Updated Articles

Trending on HCPLive

Ecnoglutide Delivers 35% Greater Weight Loss Than Semaglutide in Head-to-Head Trial

GLP-1 Discontinuation Cuts Chances of Meeting Weight Loss, Glycemic Goals in T2D

ACHIEVE-5: Orforglipron Improves Glycemic Control, Weight in T2D on Basal Insulin

VESALIUS-CV: Evolocumab Reduces Cardiovascular Events in Patients With High-Risk Diabetes

ZUPREME-1: Petrelintide Reduces Obesity, Maintains Tolerability in Phase 2 Trial